• News
  • SAN DIEGO
  • Finance

Isis gains most in 5 years on analyst praise for novel drug

Isis Pharmaceuticals Inc. (Nasdaq: ISIS) rose the most in almost five years after Cowen & Co. analyst Eric Schmidt raised his rating to outperform from neutral based on an experimental therapy's likelihood of becoming a blockbuster.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
64.81
  1.44  
+ 2.27%
2,585,695,000
77.80
22.25

Insider Trade Data

Date Insider Shares Type Value
03/24/2015 Bennett, C Frank 15,000 Sell $1,059,110
03/24/2015 Bennett, C Frank 15,000 Exchange $217,050
03/24/2015 Bennett, C Frank 15,000 Sell $1,059,110
03/24/2015 Bennett, C Frank 15,000 Exchange $217,050
03/05/2015 Geary, Richard S 18,095 Sell $1,287,383

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!